source
- GSK ends $2.2 billion brain drug partnership with Alector after trial failuresGSK and California‑based biotech Alector have ended their collaboration after both experimental brain drugs failed to meet development milestones. The partnership, announced in July 2021, gave GSK…
- Roche scraps two Ionis-partnered Huntington’s drugsThe Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.